Pharmaceuticals

ROCHE HOLDINGS AG

Roche Launches New Blood Test for Alzheimer's Pathology with CE Certification

Roche Signs Final Acquisition Agreement for PathAI

Roche Subsidiary Genentech to Release New Efficacy Data for Vabysmo

New Zealand Pharmaceutical Company Collaborates with Roche to Advance Petrelintide into Phase III Clinical Trials

Roche Reaffirms 2026 Earnings and Revenue Targets

Roche Reports 6% Strong Sales Growth at Constant Exchange Rates in Q1 2026

Roche Genentech Announces Successful Phase 3 Clinical Trial Results for Fenebrutinib, Reducing Relapse Rate by Up to 59%

Roche's ENSPRYNG Reduces Relapse Risk by 68%

FDA Accepts Roche's Gazyva/Gazyvaro Application for Treating the Most Common Form of Lupus

Roche Launches Phase III Study for Elevidys in Response to EMA Feedback

Roche Holdings AG to Release FY2026 Q1 Earnings on April 23 Pre-Market EST, Forecast Revenue USD 18.6 B

Human Pharmaceutical acquires Rivotril brand for the Indian market

Roche Launches Elecsys ApoE4 Blood Test

Roche's Breast Cancer Treatment Study Fails to Reach Primary Endpoint

Roche Signs MoU with Egyptian Health Authority for National Digital Pathology Project

Roche's Xofluza Receives Expanded Indication Approval from China's NMPA

Roche Holding's Fenebrutinib Shows Positive Results in Multiple Sclerosis Phase 3 Trials

Roche's Fenebrutinib Phase III Trial Shows 51% Reduction in Relapse Rate

Genentech's Gazyva Phase III Study for Primary Membranous Nephropathy Successful

Roche's fenebrutinib meets primary goals in PPMS trial

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

RHHVF

ABBV

RHHBY

LABU

SBIO

BeOne Medicines has received FDA approval for Beqalzi (sonrotoclax), the first BCL-2 inhibitor specifically approved for relapsed or refractory mantle cell lymphoma (MCL) in the U.S. This approval positions Beqalzi as a competitor to AbbVie and Roche's Venclexta. Beqalzi has shown to be 14 times more potent than Venclexta in preclinical assays and offers advantages in safety and convenience due to its shorter half-life. BeOne aims to expand Beqalzi's use in chronic lymphocytic leukemia (CLL), where it has demonstrated promising efficacy in trials.

Fiercepharma

Beigene

Abbvie

Roche

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VG Health

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

VanEck Biotech ETF

Eli Lilly

AstraZeneca

AstraZeneca PLC

BeOne's Venclexta challenger Beqalzi nets FDA approval

ELIL

LLYX

Roche has received European CE Mark approval for its Elecsys pTau217 Alzheimer's blood test, developed in collaboration with Eli Lilly. This test aims to detect amyloid pathology earlier in patients showing cognitive decline, potentially reducing reliance on invasive procedures. The approval is based on studies involving early-stage Alzheimer's patients, and Roche plans to expand the test's availability across Europe and potentially the U.S. later this year. Eli Lilly's stock is currently trading at approximately $976 per share, reflecting a 2.8% gain over the past month.

benzinga_article

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Biogen

Taiwan Semiconductor

S&P 500

Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) | RHHBY Stock News

StockTitan

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) | RHHBY Stock News

CPRX

EBAY

BAYRY

BLSH

This week saw significant deals across various sectors. Two Harbors Investment amended its merger with CrossCountry Mortgage to $12 per share. Roche plans to acquire PathAI for up to $1.1B. Angelini Pharma will buy Catalyst Pharmaceuticals for $31.50 per share, totaling $4.1B. Western Midstream Partners is acquiring Brazos Delaware II for ~$1.6B. Bayer agreed to acquire Perfuse Therapeutics for up to $2.45B. Bullish is set to acquire Equiniti for $4.2B. Lattice Semiconductor will buy AMI for $1.65B. eBay shares rose 13% after GameStop proposed a $125 per share acquisition.

businessinsider

Catalyst Pharma

eBay

Bayer

Bullish

GameStop

iShares US Medical Devices

Key deals this week: Roche, Bayer, eBay, Bullish, and more

LABD

Shares of Zealand Pharma rose approximately 9% after the company announced a share buyback program to repurchase nearly $200M worth of stock over the next five months. The program, managed by Danske Bank, will buy back up to 7.2M shares from May 7 to October 31, 2026. Additionally, Zealand Pharma is set to receive $700M in milestone payments from Roche this year related to its weight loss candidate, petrelintide, including $575M expected in H2 for Phase 3 trials and a $125M anniversary payment in Q2.

ROCHE HOLDINGS AG(RHHVF.US)

BeOne's Venclexta challenger Beqalzi nets FDA approval

Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) | RHHBY Stock News

Key deals this week: Roche, Bayer, eBay, Bullish, and more

Zealand Pharma climbs on share buyback program